Fig. 1From: B7-H3 is eligible for predicting clinical outcomes in lung adenocarcinoma patients treated with EGFR tyrosine kinase inhibitorsImmunohistochemical evaluation of tumoral B7-H3 expression in LUAD. A B7-H3 intensity 0 (negative). B, C B7-H3 low expression. D–F B7-H3 high expression (D cytoplasmatic staining. E Membranous staining. F Membranous and cytoplasmatic staining) (×200)Back to article page